Another Biosimilar Approval From FDA, Another Unknown Launch Date

The US Food and Drug Administration (FDA) on Friday approved Pfizer’s Zirabev (bevacizumab-bvzr), the 21st biosimilar in the US and the second for Roche’s cancer treatment Avastin (bevacizumab).